pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
149
stories
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
16d
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
20d
Trump administration tries again to institute rebates in 340B
biopharma dive
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
20d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
endpoints
21d
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
21d
Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China push
endpoints
21d
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
endpoints
21d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
21d
Sanofi records €1B+ write-off, ends work on two immunology assets
endpoints
21d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
22d
AbCellera, Vertex partner on next-gen T-cell engagers
biopharma dive
22d
7 companies hiring in New York now
biospace
22d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
23d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
23d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
27d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
27d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
27d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
27d
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
27d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
27d
A new, separate outbreak of the diarrhea-causing parasite
stat
← prev
page 2 of 5
next →
